Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DE-127 (low-dose atropine) ophthalmic solution for myopia control
jRCT2080224816Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Aug 2019
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of atropine in myopia (3 arms), sponsored by Santen Pharmaceutical. Started Aug 2019; status: completed.
02
Drugs
atropine
03
Conditions
myopia
Beyond the preview
Go deeper on jRCT2080224816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224816.